{"preliminary_commentary":{"by_channel":{"x_thread":23,"podcast":6,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03833154\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PACIFIC-4","nct_id":"NCT03833154","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pacific-4-nct03833154. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PACIFIC-4","arms":[{"description":"SBRT\n\nDurvalumab (PD-L1 monoclonal antibody) 1500 mg every 4 weeks \\[q4w\\] intravenously \\[iv\\] for up to 26 cycles or until progression or other discontinuation criteria are met.","label":"SoC SBRT + Durvalumab Therapy (Main Cohort)","type":"EXPERIMENTAL"},{"description":"SBRT\n\nPlacebo (matching placebo for infusion) every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met.","label":"SoC SBRT + Placebo Therapy (Main Cohort)","type":"PLACEBO_COMPARATOR"},{"description":"SBRT\n\nOsimertinib 80mg every day \\[qd\\] for oral administration up to 36 months or until progression. Osimertinib treatment should start within 7 to 14 days after completion of SBRT","label":"SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, open-label separate cohort)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-10-31","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":724,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Durvalumab","otherNames":["MEDI4736"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"OTHER"},{"name":"(Osimertinib cohort, single-arm, open-label separate cohort)","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-20","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-10-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1 in subpopulation of patients with Stage I/II NSCLC","timeFrame":"from randomization up to 6 years"},{"measure":"4-year Progression-Free Survival (4y-PFS) by ICR according to RECIST 1.1 criteria","timeFrame":"from treatment start up to 5 years"}],"references":[],"start_date":{"date":"2019-03-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation","url":"https://clinicaltrials.gov/study/NCT03833154"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pacific-4-nct03833154"}